In an accompanying editorial, Dr. Lars Kober and Dr. Thomas Engstrøm, of the department of cardiology at Rigshospitalet at the University of Copenhagen, wrote that until now, there had been a lack of evidence that complete revascularization could reduce hard outcomes such as death and recurrent myocardial infarction (N Engl J Med. 2019 Sep. 1. doi: 10.1056/NEJMe1910898).
However, they said, given the findings of this study, it might now be appropriate to recommend complete revascularization for patients such as those enrolled in the study.
“Better selection of high-risk patients may also refine the determination of who is most likely to benefit from complete revascularization,” they wrote.
COMPLETE was supported by the Canadian Institutes of Health Research, with additional support from AstraZeneca, Boston Scientific, and the Population Health Research Institute. Two authors declared support from AstraZeneca and Boston Scientific during the conduct of the study, and eight declared personal fees, funding, and grants from the pharmaceutical industry outside the study. One author declared employment with Medtronic, unrelated to the submitted work.
Both editorial authors declared grants and personal fees, including from the study supporters.
SOURCE: Mehta S et al. N Engl J Med. 2019 Sep. 1. doi: 10.1056/NEJMoa1907775.